Ketipine

Quetiapine, the active ingredient in Ketipine, is an atypical antipsychotic presented as an oral tablet for oral use. It is used to treat schizophrenia, bipolar disorder, and as adjunct therapy for major depressive disorder in adults.

GNH USA supplies Ketipine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketipine (quetiapine) is employed in the management of several psychiatric disorders within the psychotic and mood disorder families.

- Schizophrenia: reduces positive and negative symptoms and improves overall functioning. - Bipolar disorder: stabilises mood during manic, depressive, and mixed episodes. - Major depressive disorder (adjunct therapy): enhances antidepressant response when added to standard treatment.

Quetiapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain - Orthostatic hypotension - Dizziness

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe neutropenia - QT interval prolongation leading to arrhythmia - Severe hyperglycaemia or new‑onset diabetes - Tardive dyskinesia or other extrapyramidal symptoms

Before initiating therapy with Ketipine, consider the following safety measures.

- Cardiovascular assessment: evaluate baseline ECG and monitor for QT prolongation. - Metabolic monitoring: regularly check weight, fasting glucose, and lipid profile. - Sedation risk: advise patients about impaired alertness, especially when driving. - Orthostatic hypotension: counsel on rising slowly from sitting or lying positions. - Contraindications: avoid in patients with known hypersensitivity to quetiapine. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Quetiapine can interact with several drug classes; awareness helps minimise adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Antihypertensives: additive orthostatic hypotension. - Anticholinergic agents: may worsen dry mouth and constipation.